Human clear cell renal cell carcinoma: HLA-G expression and microvessel density analyse

PALMA MARÍA BELÉN; ANDRINI LAURA; INDA ANA MARIA; ERRECALDE ANA LÍA; CAROSELLA EDGARDO; TRONIK LE-ROUX DIANA; MIRIUKA SANTIAGO; GARCIA MARCELA

Mar del Plata

Congreso; LXIII Reunión Anual de SAIC- SAI- SAFIS; 2018

SAIC-SAI- SAFIS

Renal cell carcinomas (RCCs) are the third genitourinary malignancie, behind prostate and bladder carcinoma. The most aggressive and deadly subtype is the clear cell RCC (ccRCC). The habitual oncological treatments are radio and chemotherapy, but there is a high percentage of failure in this treatment. New strategies are being tested, like immune and angiogenesis therapy, but results are controversial. In this context, the HLA-G molecule appears as a new perspective of anti-tumor therapeutic strategy, since generates suppression and tolerance of the immune system and is expressed abnormally in some types of cancer as a mechanism of immune evasion. On the other hand, microvessel density (MVD), determined by immunohistochemical staining with CD34, is used as indicator of neoformation of sanguineous vessels. Our aim was to create a primary cell culture, using human samples from partial or radical nephrectomies to evaluate MVD and HLA-G expression. Methods: MVD was determined by CD34 staining in the tumor samples and HLA-G expression was determined by real time-PCR from cells grown from primary cell culture. Preliminary results showed that all tumor samples are HLA-G positive, but this expression is not homogeneous. Some samples expressed HLA-G only in the peripheral tumor area, others only in the central area, and others in both. No patient expressed HLA-G in the normal renal parenchyma surrounding the tumor. MVD index was observed to be higher in the peripheral tumoral area than in the central one. We can conclude that the intratumoral heterogeneity observed in the HLA-G expression as much as CD34 expression could be the reason for therapeutic failure. These knowledge, about ccRCC, is important not only for new target therapy but also to improve the diagnosis and prognosis of this important neoplasia.